Improving outcomes is at the heart of Bayer’s long-standing commitment to addressing unmet patient medical needs. Bayer’s U.S. Cardiovascular and Renal Franchise brings advancements to patients with therapies for heart failure (HF), pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and chronic kidney disease (CKD) in patients with type 2 diabetes (T2D).